Turkish Journal of Medical Sciences
Volume 46

Number 5

Article 21

1-1-2016

The efficacy of oral ribavirin on clinical and laboratory parameters
inCrimean?Congo hemorrhagic fever: an observational study from
Turkey*
GÜNAY ERTEM
MELİHA ÇAĞLA SÖNMEZER
FATİH TEMOÇİN
ÇİĞDEM ATAMAN HATİPOĞLU
NECLA TÜLEK

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
ERTEM, GÜNAY; SÖNMEZER, MELİHA ÇAĞLA; TEMOÇİN, FATİH; HATİPOĞLU, ÇİĞDEM ATAMAN; TÜLEK,
NECLA; and ORAL, BEHİÇ (2016) "The efficacy of oral ribavirin on clinical and laboratory parameters
inCrimean?Congo hemorrhagic fever: an observational study from Turkey*," Turkish Journal of Medical
Sciences: Vol. 46: No. 5, Article 21. https://doi.org/10.3906/sag-1506-92
Available at: https://journals.tubitak.gov.tr/medical/vol46/iss5/21

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

The efficacy of oral ribavirin on clinical and laboratory parameters
inCrimean?Congo hemorrhagic fever: an observational study from Turkey*
Authors
GÜNAY ERTEM, MELİHA ÇAĞLA SÖNMEZER, FATİH TEMOÇİN, ÇİĞDEM ATAMAN HATİPOĞLU, NECLA
TÜLEK, and BEHİÇ ORAL

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol46/iss5/21

Turkish Journal of Medical Sciences

Turk J Med Sci
(2016) 46: 1407-1414
© TÜBİTAK
doi:10.3906/sag-1506-92

http://journals.tubitak.gov.tr/medical/

Research Article

The efficacy of oral ribavirin on clinical and laboratory parameters in
Crimean–Congo hemorrhagic fever: an observational study from Turkey*
1,

1

2

Günay ERTEM **, Meliha Çağla SÖNMEZER , Fatih TEMOÇİN ,
1
1
1
Çiğdem ATAMAN HATİPOĞLU , Necla TÜLEK , Behiç ORAL
1
Department of Infectious Diseases and Clinical Microbiology, Ankara Education and Research Hospital, Ankara, Turkey
2
Department of Infectious Diseases and Clinical Microbiology, Yozgat State Hospital, Yozgat, Turkey
Received: 20.06.2015

Accepted/Published Online: 02.01.2016

Final Version: 17.11.2016

Background/aim: In this observational study, the effects of oral ribavirin on clinical and laboratory parameters and blood products use
in patients with Crimean–Congo hemorrhagic fever (CCHF) were evaluated.
Materials and methods: CCHF patients (n = 100) who were hospitalized between 2007 and 2010 were included. Oral ribavirin was
administered to 56 patients with symptom duration less than 5 days. Forty-four patients did not receive ribavirin (control group). The
patients that received ribavirin in the first 3 days following the initiation of symptoms were designated as Group 1 (n = 29) and the others
were designated as Group 2.
Results: Ribavirin-treated and untreated groups were similar in terms of demographic and most clinical characteristics. Leukocyte
and platelet counts were lower in the ribavirin group than in the control group, but values of prothrombin time, activated partial
thromboplastin time, aspartate aminotransferase, creatinine phosphokinase, and lactate dehydrogenase were higher (P = 0.011, P =
0.015, P = 0.001, P = 0.001, P = 0.021, P = 0.019, P = 0.004, respectively). Platelet concentrates use was greater in the ribavirin group (P
= 0.01).
Conclusion: No positive effects of oral ribavirin on blood products use or clinical or laboratory parameters of CCHF patients were
observed. Moreover, no difference was shown between early and late initiation of ribavirin.
Key words: Crimean–Congo hemorrhagic fever, ribavirin, clinical parameters, laboratory parameters

1. Introduction
Crimean–Congo hemorrhagic fever (CCHF) is a viral
hemorrhagic disease with high fatality. The CCHF virus
infects people by tick bites and contact with the blood
or tissue of infected people or viremic livestock (1). The
first case in Turkey was reported in 2002. Later cases have
been reported from Eastern and Central Anatolia and
the Central-Eastern Black Sea Region (2,3). The number
of confirmed cases was 9069 at the end of 2014 (Data
of Ministry of Health of Turkey; obtained by personal
communication).
Today, there is no specific treatment for CCHF.
Monitoring of the patient and supportive treatment
consisting of replacement of blood products are the main
principles of treatment (4,5). Although use of ribavirin

is suggested by the World Health Organization and
Centers for Disease Control and Prevention, the efficacy
of ribavirin as an antiviral drug is controversial (available
http://www.who.int/mediacentre/factsheets/fs208/en and
at:
http://www.cdc.gov/vhf/crimean-congo/treatment/
index.html). Ribavirin, which is used for the treatment of
viral hemorrhagic fever syndromes, was shown to inhibit
the growth of CCHF virus in animal models and in vitro
(6,7). Many observational and case-control studies were
reported in Turkey, Iran, and Pakistan in which oral and
intravenous ribavirin was used for treatment (8,9–20).
Recently, two systemic reviews and meta-analyses were
published evaluating the efficacy of ribavirin (21,22). Yet,
whether ribavirin is effective has not been clarified. The
aim of the present study was to evaluate the effects of oral

* Partial results of this study were presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna,
		 Austria, 10–13 April 2010.
** Correspondence: tuncergunay@yahoo.com
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ribavirin on clinical and laboratory parameters and blood
products use in CCHF patients who were followed in a
tertiary care center.
2. Materials and methods
This retrospective study was conducted in the 670bed Ankara Training and Research Hospital in Central
Anatolia. All patients with CCHF hospitalized between
2007 and 2010 at the First Department of Infectious
Diseases and Clinical Microbiology were included in the
study. The study group comprised severe patients who
were transferred from rural areas according to regulations
on CCHF by the Health Ministry of Turkey. Diagnosis was
confirmed by CCHF IgM and/or RT-PCR positivity in
serum samples taken on admission and 1 week later. Tests
were run at the Reference Laboratory of the Public Health
Institute of Turkey.
According to requirements all patients received
supportive therapy including fluid, fresh frozen plasma
(FFP), and platelet and erythrocyte concentrates. Informed
consent was obtained from the patients. At the time of
admission, oral ribavirin was administered to the patients
whose symptoms were shorter than 5 days and who had
no contraindications such as renal failure. The patients
whose symptoms were longer than 5 days did not receive
ribavirin because viremia is decreasing in the second week
of the disease. These patients were defined as the control
group. Dosage of oral ribavirin was 2 grams as an initial
loading dose, then 1 g q.i.d. for 4 days, and then 0.5 g q.i.d.
for 6 days (11,23).
The patients who were treated with ribavirin were
grouped according to receiving ribavirin within 3 days
of the onset of symptoms (Group 1) or after the 3rd day
(Group 2). The patients’ clinical symptoms, signs, and
laboratory findings [aspartate aminotransferase (AST),
alanine aminotransferase (ALT), lactate dehydrogenase
(LDH), creatinine phosphokinase (CPK), leukocyte,
hemoglobin (Hb), platelet, activated partial thromboplastin
time (APTT), prothrombin time (PT)] were recorded.
Various clinical findings were compared to evaluate the
efficacy of ribavirin. Moreover, the differences between the
laboratory values on the 1st and 5th days of admission were
compared. Statistical analysis was performed using SPSS
(Chicago, IL, USA). Comparisons of categorical variables
were performed by chi-squared test. According to results
of the normality test, Student’s t-test, Mann–Whitney
U test, or Kruskal–Wallis test were used to compare the
means or medians of continuous variables. P values < 0.05
were considered significant.
3. Results
The number of the patients was 100 (56 in the ribavirin
group and 44 in the control group) and 15 of them was
diagnosed by IgM and 85 by RT-PCR positivity. The mean
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duration between onset of symptoms and admission to
our hospital was 3.7 ± 2.2 days. The ribavirin-treated and
untreated groups were similar in terms of age, sex, history
of tick contact, location of residence, and duration of
symptoms (P > 0.05) (Table 1). Myalgia, fever, headache,
vomiting, and bleeding were the most frequent symptoms.
Both groups were similar at the time of admission in terms
of symptoms and findings except nausea and abdominal
pain. Nausea and abdominal pain were more frequent in
the ribavirin group (P = 0.01 and P = 0.037, respectively)
(Table 1). Initial laboratory values at the time of admission
were significantly more deteriorated in the ribavirin group
than they were in the controls. Leukocyte and platelet
counts were lower and values of APTT, PT, AST, CPK,
and LDH were higher in the ribavirin group than in the
control group (P = 0.011, P = 0.015, P = 0.001, P = 0.001, P
= 0.021, P = 0.019, P = 0.004, respectively). The differences
for the remaining laboratory values were statistically
insignificant (P > 0.005 for all comparisons). Duration of
hospitalization was longer in the ribavirin group compared
to the control group (8 vs. 7 days, P < 0.001). The median
duration from onset of symptoms to hospital admission
was longer in Group 2 than in Group 1 (5 vs. 2 days, P =
0.000). Diarrhea was more frequent (P = 0.038) and the
median PT values were longer in Group 2 (11.4 vs. 13.2 s,
P = 0.028) (Table 2). The overall case fatality rate was 2%.
One of the 2 patients who died received ribavirin but the
other did not (P = 0.689).
When evaluating the efficacy of ribavirin, fever
decreased earlier in the control group than in the ribavirin
group (1 day vs. 2 days, P = 0.001), but there was no
statistical significance for duration of bleeding cessation
between the groups. The difference for platelet counts was
less in the ribavirin group compared to the control group
(P = 0.031). No significant difference was found between
the groups in terms of other laboratory parameters. Use of
platelet concentrates was greater in the ribavirin group (P
= 0.01). However there was no statistical difference for use
of FFP (P > 0.005) (Table 3).
When the efficacy of early or late initiation of
ribavirin was evaluated, fever decreased earlier in the
control group than in both Group 1 (1 day vs. 2.5 days,
P = 0.015) and Group 2 (1 day vs. 2 days, P = 0.001).
No statistical significance was found between Groups
1 and 2 for resolution of fever. Moreover, there was no
statistical significance for duration of bleeding cessation
between Group 1, 2, and the control group. Platelet counts
increased most rapidly between the 1st and 5th days of
admission in the control group (P = 0.027). A significant
difference was found between Group 2 and the control
group for platelet counts (P = 0.007). Prothrombin time
values decreased most rapidly in Group 2 (P = 0.007). A
significant difference was detected between Group 1 and
Group 2, and between Group 2 and the control group for
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Table 1. Demographic and baseline clinical and laboratory findings of the patients with CCHF.
Ribavirin group
(n = 56)

Control group
(n = 44)

P

Age (years) (mean ± SD)

46.88 ± 17.46

46.27 ± 17.36

0.864

Female sex, n (%)

33 (57.9)

21 (48.8)

0.181

Tick bite history, n (%)

36 (64.3)

28 (63.6)

0.556

Living in rural area, n (%)

51 (91.1)

35 (79.5)

0.088

Median (range) duration from onset
of symptoms to hospital admission

4 (1–8)

3 (1–12)

0.658

Median (range) duration of hospitalization

8 (4–24)

7 (1–12)

<0.001

Bleeding

18 (32.1)

11 (25)

0.289

Fever

43 (76.8)

35 (79.5)

0.467

Confusion

3 (5.4)

1 (2.3)

0.405

Myalgia

46 (82.1)

32 (72.7)

0.188

Headache

26 (46.4)

14 (31.8)

0.101

Abdominal pain

12 (21.4)

3 (6.8)

0.037

Diarrhea

10 (17.9)

5 (11.4)

0.17

Nausea

44 (78.6)

24 (54.5)

0.01

Vomiting

20 (35.7)

11 (25)

0.176

Maculopapular rash

5 (8.9)

5 (11.4)

0.469

Hepatosplenomegaly

2 (3.6)

2 (4.5)

0.649

Leukocytes (/mm3)

1800 (157–11,200)

2500 (100–10,000)

0.011

Hb (g/dL)

13.4 (6.6–18.2)

14.1 (6.8–17.5)

0.128

Platelets (×103)

44.5 (5–150)

65 (6–314)

0.015

APTT (s)

41.2 (31.3–82.3)

34.95 (23.9–105.8)

0.001

PT (s)

12.3 (9.7–34.5)

10.7 (8.9–17)

0.001

ALT (U/L)

93.5 (10–734)

78 (10–1089)

0.309

AST (U/L)

232 (29–1055)

91.5 (21–657)

0.021

CPK (U/L)

319 (55–3796)

206 (37–1920)

0.019

LDH (U/L)

576.5 (190–2781)

367 (139–6105)

0.004

Demographic characteristics

Symptoms and signs, n (%)

Laboratory findings, median (range)

SD, standard deviation; Hb, hemoglobin; APTT, activated partial thromboplastin time; PT, prothrombin time; ALT,
alanine transaminase; AST, aspartate transaminase; CPK, creatinine phosphokinase; LDH, lactate dehydrogenase.
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Table 2. Demographic, baseline clinical and laboratory findings of the patients treated with ribavirin.
Group 1
(n = 29)

Group 2
(n = 27)

P

Age (years) (mean ± SD)

47.7 ± 15.1

46.5 ± 18.6

0.825

Female sex, n (%)

16 (55.2)

17 (63)

0.554

Median (range) duration from onset
of symptoms to hospital admission

2 (1–5)

5 (4–8)

0.000

Median (range) duration of hospitalization

8 (4–16)

9 (4–24)

0.078

Bleeding

10 (34.5)

8 (29.6)

0.698

Fever

22 (75.9)

21 (48.8)

0.865

Confusion

1 (3.4)

2 (7.4)

0.511

Myalgia

22 (75.9)

24 (88.9)

0.299

Headache

12 (41.4)

14 (51.9)

0.432

Abdominal pain

4 (13.8)

8 (29.6)

0.149

Diarrhea

2 (6.9)

8 (29.6)

0.038

Nausea

25 (86.2)

19 (70.4)

0.199

Vomiting

12 (41.4)

8 (29.6)

0.359

Maculopapular rash

2 (6.9)

3 (11.1)

0.664

Hepatosplenomegaly

0 (0)

2 (7.4)

0.228

Leukocytes (/mm3)

1800 (157–3600)

1900 (800–11,200)

0.131

Hemoglobin (g/dL)

13.4 (6.6–16)

13.4 (9.4–18.2)

0.844

Platelets (×103)

44 (7–123)

48 (5–150)

0.617

APTT (s)

39.2 (31.3–74.6)

42.1 (32.5–82.3)

0.207

PT (s)

11.4 (9.7–34.5)

13.2 (10.1–33.3)

0.028

ALT (U/L)

96 (10–734)

88 (14–438)

0.528

AST (U/L)

217 (37–1055)

242 (29–790)

0.646

CPK (U/L)

311 (55–3796)

327 (74–1817)

0.863

LDH (U/L)

569 (247–2781)

615 (190–1693)

0.922

Demographic characteristics

Symptoms and signs, n (%)

Laboratory findings, median (range)

SD, standard deviation; Hb, hemoglobin; APTT, activated partial thromboplastin time; PT, prothrombin time; ALT,
alanine transaminase; AST, aspartate transaminase; CPK, creatinine phosphokinase; LDH, lactate dehydrogenase.
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Table 3. Comparison of clinical and laboratory characteristics and blood products use in ribavirin-treated and untreated patients.*
Ribavirin group
(n = 56)

Control group
(n = 44)

P

Duration of fever resolutiona (days)

2 (1–7)

1 (1–4)

0.001

Duration of bleeding cessation (days)

3 (1–4)

1 (1–6)

0.127

b

Difference between laboratory values on the 5th and 1st day

c

Leukocytes (/mm3)

1350 (–6700–11,400)

2050 (–4400–8400)

0.147

Hb (g/dL)

–0.25 (–4.2–3)

–0.6 (–9.7–4.6)

0.157

Platelets (×10 )

14 (–56–144)

58.5 (–41–175)

0.031

APTT (s)

–6.35 (–33.5–25.1)

–7.45 (–48.9–9)

0.59

PT (s)

–0.68 (–17.3–4.2)

–0.3 (–5.5–9.1)

0.255

ALT (U/L)

4 (–571–326)

0.5 (–576–250)

0.997

AST (U/L)

–35.5 (–648–470)

–12.5 (–416–240)

0.576

CPK (U/L)

–156 (–3666–495)

–127.5 (–1845–4941)

0.234

LDH (U/L)

–156.5 (–2631–567)

–90 (–2069–143)

0.361

Platelet concentrates

1 (0–15)

0 (0–61)

0.01

FFP

0 (0–20)

0 (0–19)

0.401

3

Given blood product (units)

*Data were presented as median (range).
a
Analysis was performed for patients with fever (n = 78).
b
Analysis was performed for patients with bleeding (n = 29). cNegative values indicate descending laboratory findings on the 5th day.
SD, standard deviation; Hb, hemoglobin; APTT, activated partial thromboplastin time; PT, prothrombin time; ALT, alanine transaminase;
AST, aspartate transaminase; CPK, creatinine phosphokinase; LDH, lactate dehydrogenase; FFP, fresh frozen plasma.

PT values (P = 0.011 and P = 0.004, respectively). However,
there was no difference between the three groups in
terms of the other laboratory parameters. Use of platelet
concentrates was least in the control group (P = 0.037). A
significant difference was detected between Group 1 and
the control group, and between Group 2 and the control
group for platelet concentrates use (P = 0.025 and P =
0.031, respectively). There was no significant difference
between the three groups in terms of need for FFP (Table
4). Erythrocyte concentrates could not be compared due
to limited use. No adverse reactions were detected due to
ribavirin.
4. Discussion
Ribavirin was given to CCHF patients who were admitted
to a tertiary care hospital and had symptoms that had
started less than 5 days earlier. Oral ribavirin is used
because there is no intravenous form of ribavirin in Turkey.
In this study, no effect of ribavirin on the improvement
of clinical and laboratory parameters and blood products
use was detected. The longer duration of hospitalization in

the patients who received ribavirin could be related to the
poorer laboratory findings of these patients, even though
the clinical characteristics were similar. Additionally,
patients who received ribavirin were discharged later
depending on the duration of treatment.
Many observational and case-control studies in which
ribavirin has been used for treatment have begun to
increase by taking in vivo and in vitro studies as examples
(8–20). In some of these studies no positive effect of
ribavirin was shown on the prognosis of the disease
compared to the control group (9,16,18). These three
studies included patients who were transferred to tertiary
centers because of severity of the disease as in our study. In
the quasi-experimental, multicenter study by Elaldi et al.
(9) no decline in fatality attributable to ribavirin was found.
Only the need for platelet concentrate and FFP was lower
in the patients who received ribavirin. In our study, use of
platelet concentrates was greater in Groups 1 and 2. This
may be related to the low platelet values in the ribavirintreated patients. The transferred patients were severe cases.
Furthermore, duration of symptoms until admission to the
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Table 4. Comparison of clinical and laboratory characteristics and blood products use in early, late, and untreated patients.*
Group 1
(n = 29)

Group 2
(n = 27)

Control group
(n = 44)

P

Duration of fever resolutiona (days)

2.5 (1–6)c

2 (1–7)c

1 (1–4)d

0.002**

Duration of bleeding cessationb (days)

2 (1–4)

3.5 (2–4)

1 (1–6)

0.148

Difference between laboratory values on the 1st and 5th dayse
Leukocytes (/mm3)

1600 (–200–3300)

1000 (–6700–11,400)

2050 (–4400–8400)

0.26

Hb (g/dL)

0.1 (–4.2–2)

–0.4 (–4.2–3)

–0.6 (–9.7–4.6)

0.274

Platelets (×103)

20 (–54–144)

7 (–56–108)c

58.5 (–41–175)d

0.027**

APTT (s)

–6.3(–33.5–20.1)

–6.5 (–33.1–25.1)

–7.45 (–48.9 – 9)

0.632

PT (s)

–0.13 (–17.3–2.6)

–1.6 (–13–4.2)

–0.3 (–5.5–9.1)

0.007**

ALT (U/L)

2000 (–571 – 326)

6 (–362–193)

0.5 (–576–250)

0.953

AST (U/L)

–65 (–648–153)

–25 (–598–470)

–12.5 (–416–240)

0.484

CPK (U/L)

–169 (–3666–254)

–142 (–1493–495)

–127.5 (–1845–4941)

0.333

LDH (U/L)

–166 (–2631–191)

–109 (–1132–567)

–90 (–2069–143)

0.625

Platelet concentrates

1 (0–8)c

1 (0–15)c

0 (0–61)d

0.037**

FFP

0 (0–20)

0 (0–20)

0 (0–19)

0.697

d

c

d

Given blood product (units)

*Data were presented as median (range).
Analysis was performed for patients with fever (n = 78).
b
Analysis was performed for patients with bleeding (n = 29).
e
Negative values indicate descending laboratory data on the 5th day.
**There is a significant difference between c and d.
For duration of fever resolution; P = 0.015 (Group 1 and the control); P = 0.001 (Group 2 and the control)
For PLT, P = 0.007 (between Group 2 and the control).
For PT, P = 0.011 (Group 1 and Group 2); P = 0.004 (Group 2 and the control).
For PLT concentrates, P = 0.025 (Group 1 and the control); P = 0.031 (Group 2 and control)
a

hospital was long [median: 3.5 (1–12) days]. The delay of
initiation of ribavirin in these patients could be one of the
parameters affecting the antiviral response.
The studies that examined the positive effects of
ribavirin on clinical and/or laboratory parameters have
mostly been reported from Turkey, Iran, and Pakistan
(8,10,12,14,15,17,19,20). In their retrospective cohort
study, Fisgin et al. (14) reported that laboratory values
improved earlier in the group that received ribavirin
earlier compared to both of the groups that did not receive
or received it later. The efficacy of early or late initiation
of ribavirin was not assessed in our study. Additionally,
platelet counts increased rapidly in the control group. This
condition may have been caused by unfavorable laboratory
parameters in the patients that received ribavirin.
Moreover, early decline of platelet counts in the patients
who received ribavirin late may be due to clinical progress
of the disease.
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Because there is no definite recommendation about the
effect of ribavirin in CCHF, some centers in Turkey give
ribavirin but some use only supportive treatment. In a
study about the epidemiology of CCHF, it was determined
that although the use of ribavirin decreased from 67.9%
to 21.8% between 2004 and 2007 in Turkey, the fatality
rates did not change (5.2% in 2004, 4.6% in 2007) (24).
According to data from the Ministry of Health of Turkey,
the fatality rate was 4.8% in 2014. The effect of ribavirin on
fatality could not be evaluated in our study because two
patients died.
To date, only one randomized study about ribavirin
use in CCHF patients has been conducted, by Koksal et al.
(13). In their study (n = 136 patients), no positive effect of
ribavirin was determined on clinical or laboratory findings.
The two meta-analyses and a systemic review reported
to date were not sufficient to clarify the discussions. The
authors pointed out the inadequate level of evidence, the

ERTEM et al. / Turk J Med Sci
high risk of bias, the heterogeneity of the patients, and the
time of ribavirin initiation as common problems (21,22).
However, Soares-Weiser et al. (22) suggested that ribavirin
treatment could reduce mortality by 44% according to the
results of selected observational studies. In a review about
the treatment of CCHF, ribavirin is recommended in
suspected cases until new data are provided, even though
its efficacy has not been fully confirmed (25).
Our study has some limitations. First of all, this was
an observational study including a small sample size.
Application of supportive treatment to all patients may be
considered a confounding factor in the study. In addition,
it was not possible to choose case and control groups with
all characteristics similar. Unfortunately this increased the

risk of bias. Ribavirin could be administered late because
the study was conducted with transferred patients. The
effect of ribavirin on mortality was not evaluated, which
is another limitation. Moreover, detection of viral load
as an independent predictor of mortality could not be
performed.
In conclusion, in our observational study, no positive
effects of oral ribavirin on blood products use or clinical
or laboratory parameters in CCHF patients were
determined. Considering the risk of fatal prognosis in
severe cases, we suggest that well-designed randomized
trials should be planned to evaluate the efficacy of ribavirin
in CCHF.
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